However to our knowledge, this is the first study to conduct a comprehensive investigation into the changes that occur to multiple members of the pathway in the transition from clinical hormone-sensitive to -refractory prostate cancer, and in particular, to test if phosphorylation of AR is associated with patient outcome measures. This evidence concerns the gene AR and prostate carcinoma.